- Medidata Rave Omics Machine Learning Identifies New Evidence of Biomarkers in Rare Disease Research by the Castleman Disease Collaborative Network
-
Memorial Sloan Kettering Cancer Center (MSK) Monitors Newly Diagnosed Myeloma Patients with Medidata ePRO
NEW YORK – Nov. 20, 2018 – The Castleman Disease Collaborative Network (CDCN) will present results of a large-scale proteomics study of idiopathic multicentric Castleman disease (iMCD), supported by Medidata Rave Omics, at the 60th Annual Meeting of the American Society of Hematology. The CDCN will also share an overview of its poster presentation and abstract at the Medidata (NASDAQ: MDSO) booth (#257).
The CDCN, a global non-profit organization dedicated to accelerating research and treatments for Castleman disease, in collaboration with Medidata Rave Omics, will share an overview of its serum proteomics study abstract at the Medidata booth on December 2 at 2 p.m. The CDCN’s research findings presented at ASH include:
-
Identification of six proteomically unique iMCD disease subtypes or disease states
-
Evidence of proteomic predictors of anti-interleukin-6 treatment response
-
Etiological insights into the poorly understood rare disease
CDCN and Medidata speakers:
-
Dustin Shilling, Castleman Disease Collaborative Network
-
David Lee, chief data officer, Medidata
Memorial Sloan Kettering Cancer Center (MSK) will also present new research supported by the Medidata Rave Patient Cloud at ASH. The aim of the study is to assess whether the use of mobile wearable technology establishes patterns of “sleep” and “wake” states in newly diagnosed patients receiving therapy, and if these patterns differ over time. Activity, sleep data, and completed patient reported outcome (ePRO) questionnaire data were automatically synced and transferred to the Medidata Rave platform.
Learn more about Medidata at ASH 2018.
About Medidata
Medidata is leading the digital transformation of life sciences, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by the #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
About Castleman Disease Collaborative Network (CDCN)
CDCN is a global initiative dedicated to accelerating research and treatment for Castleman disease (CD) to improve survival for all patients with CD. The CDCN’s innovative approach first involved building a global community of over 400 physicians and researchers, assembling a scientific advisory board of 28 experts from eight countries, and supporting and engaging patients in research prioritization. Then, the CDCN crowdsourced among the global community to identify gaps in medical knowledge and determine high priority research projects. In parallel, the CDCN connects and supports thousands of CD patients around the world. Now, the CDCN recruits top researchers to conduct studies, and works with patients, loved ones, and the public to raise funding to enable these studies. More information is available at: www.CDCN.org
Medidata:
Investors:
Betsy Frank, +1 917-522-4620
Media:
Erik Snider, +1 646-362-2997